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Abstract 
Due to distinctive features including genome architecture, population diversity, breed structure and breed-
specific disorders, the domestic dog (Canis familiaris) is becoming an important animal to study the 
genetics of morphology, behaviour and disease susceptibility in mammals [1]. Further, with around 360 of 
the some 450 diseases in dogs similar to that of human diseases, dogs provide a valuable model to 
identify the genetic causes of many diseases in humans [1]. Thus, one of the goals in canine biology is to 
better define the genetic and phenotypic diversity that exists between the 400 dog breeds [2]. Therefore, 
our groups have begun to explore the diversity in the gene encoding the canine P2X7 receptor (P2RX7) 
and its impact on receptor function in this species [3], as well as the role of this receptor in dogs [4-8]. 
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Due to distinctive features including genome architecture, 
population diversity, breed structure and breed-specific dis-
orders, the domestic dog (Canis familiaris) is becoming an 
important animal to study the genetics of morphology, be-
haviour and disease susceptibility in mammals [1]. Further, 
with around 360 of the some 450 diseases in dogs similar 
to that of human diseases, dogs provide a valuable model to 
identify the genetic causes of many diseases in humans [1]. 
Thus, one of the goals in canine biology is to better define the 
genetic and phenotypic diversity that exists between the 400 
dog breeds [2]. Therefore, our groups have begun to explore 
the diversity in the gene encoding the canine P2X7 receptor 
(P2RX7) and its impact on receptor function in this species 
[3], as well as the role of this receptor in dogs [4-8].
The P2X7 receptor is a trimeric ligand-gated cation channel, 
which is activated by extracellular adenosine triphosphate 
(ATP) and important in the release of pro-inflammatory me-
diators such as prostaglandins and cytokines of the inter-
leukin-1 family [9]. As such, P2X7 has established roles in 
inflammation, inflammatory disorders and pain [10]. In hu-
mans, the gene encoding P2X7 is highly polymorphic with at 
least 15 non-synonymous (missense) single nucleotide poly-
morphisms (SNPs) encoding for receptors with either a loss 
or gain of function [11]. Of note, a number of these SNPs are 
associated with either increased susceptibility or resistance 
to behavioural disorders, bone disease, infection, inflamma-
tory disorders or pain [11].
The canine P2RX7 gene is located on chromosome 26, and 
like its human orthologue, contains 13 exons [12]. Also simi-
lar to humans, the canine P2RX7 gene encodes a receptor 
subunit 595 amino acid residues in length [3,13] with in-
tracellular N- and C-termini, two trans-membrane domains 
and an extracellular loop containing ATP binding sites [14]. 
In contrast to humans, the canine P2X7 subunit contains an 
additional asparagine residue in the extracellular loop be-
tween positions 281 and 282, and lacks one residue in the 
C-terminus [3,13] corresponding to Thr541 in the human 
and mouse P2X7 subunits or Iso541 in the rat P2X7 subunit 
[14] (Figure 1). The functional impacts of these two amino 
acid differences have not been formally investigated. The ad-
ditional asparagine residue lies within a key structural re-
gion of the extracellular loop, which interacts with the ATP-
binding site and undergoes conformational changes during 
receptor activation [14]. However canine P2X7 is functional 
in dogs [4,6] and displays pharmacological properties simi-
lar to that of the human orthologue [8,13]. Thus, current evi-
dence suggests that this additional asparagine residue has 
little impact on receptor function. In contrast, the absence of 
the isoleucine corresponding to residue 541 in rat receptors 
most likely prevents the calcium-dependent facilitation of 
canine P2X7-mediated currents. In rat P2X7, a 17 amino acid 
sequence commencing at Iso541 forms a calmodulin-binding 
motif, responsible for the calcium-dependent facilitation of 
rat P2X7-mediated currents [15]. Importantly this isoleucine 
residue is necessary for both the calcium-dependent facilita-
tion of rat P2X7-induced currents and the binding of calmod-
ulin to this receptor [15]. In contrast, neither of these events 
occur with human P2X7, which contains Thr541 [16]. Collec-
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tively, this indicates that canine P2X7, which lacks Iso541, is 
also unlikely to undergo significant calcium-dependent facil-
itation and to bind calmodulin. The physiological relevance 
of the presence or absence of the calmodulin-binding motif 
in mammalian P2X7 remains to be established.
Figure 1. The canine P2X7 receptor subunit. Triangles represent 
additional (ins) or absent (del) amino acid residues in canine P2X7 
compared to human (or rat) P2X7. Circles represent missense sin-
gle nucleotide polymorphisms in canine P2X7 resulting in either 
loss of function (red), possible gain (green) or partial loss (orange) 
of function, or neutral effect on function (blue). Coloured lines rep-
resent a calcium-independent facilitation current motif (lime), a 
pore sensibility and activation domain (purple), or a calmodulin 
binding site (green) as previously described [20].
Recently our group cloned English Springer Spaniel P2X7, 
and has assessed the functional impact of P2X7 variation in 
a random sample of the canine population, which included 
23 different breeds and a variety of cross breeds [3]. As a 
result of this study, we identified three novel missense SNPs 
(Arg270Cys, Arg365Gln and Leu440Phe) and confirmed the 
presence of two previously reported missense SNPs (Phe-
103Leu, rs23314713; Pro452Ser, rs23315462) (Figure 1). 
Of these five SNPs, the Arg270Cys SNP resulted in an almost 
complete loss of receptor function despite normal surface 
expression in cells. This SNP was found only in heterozygous 
dosage with an allele frequency of 0.01, and appeared to be 
associated with the Pro452Ser SNP and with Cocker Span-
iels. Structural modeling of human P2X7 places Arg270 in 
the lower body of the extracellular loop and away from the 
ATP-binding site [14], but how the Arg270Cys SNP impairs 
receptor function remains unknown. A partial loss of func-
tion SNP (Arg270His, rs7958311) is present in human P2X7 
[17], indicating an important role for Arg270 in functional 
P2X7 receptors. Of clinical relevance, the Arg270His SNP 
is associated with reduced post-mastectomy pain in breast 
cancer patients, as well as with reduced pain in patients with 
osteoarthritis [18]. Thus, the Arg270Cys SNP may also be as-
sociated with reduced pain sensitivity in Cocker Spaniels or 
other breeds possibly encoding this SNP.
Of the other canine P2X7 SNPs identified, the Phe103Leu 
and Arg365Gln SNPs may be partial loss-of-function muta-
tions. However the current body of evidence is limited as to-
tal P2X7 expression was also lower in the heterologous cell 
assay used [3]. This may reflect either differences in trans-
fection efficiency or real differences in protein expression. 
The Phe103Leu SNP was frequently observed in dogs with 
an allele frequency of 0.38 [3], and Phe103 is conserved in 
human and rodent P2X7 suggesting that this residue is im-
portant in P2X7 function. Notably the first cloned canine 
P2X7 (which contains Leu103) displays an agonist profile 
[13] different to that of the cloned English Springer Spaniel 
P2X7 (which contains Phe103) [3,8]. In these latter studies 
ATP was shown to be a partial agonist of English Springer 
Spaniel P2X7 compared to 2’(3’)-O-(4-benzoyl)benzoyl ATP 
(BzATP) [3,8], while in the former study, BzATP was a par-
tial agonist compared to ATP [13]. Given that residue 103 
is in the extracellular loop of the P2X7 subunit, which con-
tains the ATP binding sites, it is possible that this residue 
contributes to ATP and BzATP sensitivity, and that the Phe-
103Leu SNP may modulate ATP binding in vivo. In contrast 
to the high frequency of the Phe103Leu SNP, the Arg365Gln 
SNP had an allele frequency of 0.03, was only found in het-
erozygous dosage, and appeared to be associated Labrador 
Retrievers [3]. Arg365, which is conserved in the equivalent 
positions in human and rodent P2X7, lies within a motif that 
contributes to calcium-independent facilitation of P2X7-me-
diated currents [16], however the contribution of Arg365 to 
this action remains unknown.
Evidence indicated the Leu440Phe SNP may cause a partial 
gain of P2X7 function, but this SNP was only observed in the 
cloned English Springer Spaniel P2X7 receptor [3]. Thus, it 
remains uncertain if this variant is a mutation arising from 
the cloning process, or a SNP present in this or possibly 
some other breeds. However Leu440 is conserved in equiva-
lent positions in human and rodent P2X7, and resides within 
a regulatory region of P2X7 [19], termed the pore sensibility 
and activation domain by others [20]. Thus, it remains pos-
sible that the residue at position 440 may partly modulate or 
regulate P2X7 function.
In contrast to the other canine P2X7 SNPs, the Pro452Ser 
SNP had a neutral effect on P2X7 function [3]. This SNP had 
an allele frequency of 0.39 in our cohort and also resides 
within the pore sensibility and activation domain. Further, 
this SNP is (somewhat serendipitously) located at the equiv-
alent position of a partial loss-of-function SNP (Pro451Leu) 
in murine P2X7 [21]. The different impact of these SNPs on 
canine and murine P2X7 function most likely reflects the dif-
ferences in physical properties between serine and leucine 
residues.
Recent findings therefore demonstrate the presence of at 
least five missense SNPs in the canine P2RX7 gene, four of 
which may alter function. Of these SNPs, the Arg270Cys SNP 
is potentially the most important. This SNP caused an almost 
complete loss of receptor function and a similar SNP (Ar-
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g270His) at the equivalent position in human P2X7 is asso-
ciated with reduced pain sensitivity. Whether the Arg270Cys 
SNP has an important pathophysiological role in dogs, such 
as reduced pain sensitivity, remains to be established. Fur-
ther, the other SNPs in the canine P2RX7 gene require fur-
ther investigation before a conclusion can be made about 
their impact on receptor function and any potential associa-
tion with disorders in dogs. Nevertheless these recent find-
ings provide a basis from which further investigations into 
the role of P2X7 and its polymorphic variants in canine biol-
ogy can be made.
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